You are here


Angiochem is a clinical-stage biotechnology company developing a new class of breakthrough drugs to treat brain diseases and brain-related disorders.

Moving beyond the barrier of proof and currently in clinical and preclinical studies, these novel pharmaceuticals are composed of small molecules and biologics designed to treat brain cancer, Parkinson's disease, type 2 diabetes/obesity, pain, and other unmet medical needs.

Learn more about the Technology Platform.

Robust Product Pipeline

Angiochem’s novel pharmaceuticals are currently being investigated in a number of
preclinical and clinical studies, and have been published in several scientific publications.